Modern Slavery Act Transparency

AMICUS THERAPEUTICS UK LIMITED

UK MODERN SLAVERY ACT STATEMENT

Amicus Therapeutics UK Limited (“Amicus UK”) makes this statement pursuant to Section 54, Part 6 of the U.K. Modern Slavery Act 2015 and it sets out the steps Amicus UK have taken to ensure that slavery and human trafficking are not taking place in its supply chain and businesses. It covers Amicus UK’s financial year from January 1, 2018 to December 31, 2018.

Our business

Amicus UK is a subsidiary of Amicus Therapeutics Inc. (Nasdaq:FOLD) which is a global, patient-dedicated group of companies focused on discovering, developing and delivering medicines for people living with rare genetic and metabolic diseases (“the Amicus Group”).

This statement is made by and relates to Amicus UK only.

The Amicus Group will begin a Modern Slavery Compliance Program to cover all its global activities.

Modern Slavery

The Amicus Group, including Amicus UK opposes the use of child labour and any form of forced labour including slavery and slave labour, and it expects the same from its business partners and suppliers. The Amicus Group, including Amicus UK is committed to compliance with all applicable laws, including the U.K.'s Modern Slavery Act.

Amicus UK’s supply chain is comprised mostly of (i) suppliers of direct materials (active ingredients, manufacturing and packaging materials) and (ii) suppliers of indirect services (professional services, facilities, sales and marketing agencies and clinical research organizations).

Amicus UK is developing its Modern Slavery compliance program and accordingly, is providing its suppliers with a modern slavery questionnaire over the course of 2019 / 2020.

Amicus Code of Conduct and Compliance Programme

The Amicus Group maintains written policies, procedures and guidelines, which includes the Amicus Code of Conduct, in which the Amicus Group communicates its ethical principles and high expectations of integrity from all the employees and contractors of any group company including Amicus UK.

In particular, the Amicus Code of Conduct at Section 3.2 commits all Amicus Group companies including Amicus UK to never using child or forced labour and to terminate the relationship with any supplier who is found to be violating this principal.

As part of the Amicus’ Ethics and Compliance programme, Amicus UK’s employees receive training on and must adhere to its Code of Conduct. The Code of Conduct and the various written policies and training programs that support it, are designed to create a culture of ethics and integrity and to facilitate compliance with the laws of all jurisdictions in which Amicus UK operates.

Amicus UK’s written agreements with its business partners require compliance with all applicable laws and regulations as well as the right to audit and visit any site to review the services provides by such vendors or suppliers.

The Amicus’ Ethics and Compliance programme provides relevant training and multiple channels of communication through which Amicus UK employees, contractors and business partners can report concerns regarding potential misconduct (including directly or through Amicus’ Hotline (“Speak Up!”) or website) without fear of retaliation. All Amicus Group companies including Amicus UK take all such reports very seriously and undertakes appropriate actions where warranted.

Next Year

During 2019 and 2020, we will take the following steps to detect and prevent modern slavery and other labour rights violations:

  • Begin our Modern Slavery compliance program to encompass all the Amicus Group companies’ activities around the world.
  • Raise further awareness with Amicus UK employees by providing specific training on Modern Slavery.
  • Designate an Amicus UK board member who will responsible for the production of future Modern Slavery Statements.

This Statement has been approved by the Board of the Directors of Amicus Limited of Amicus UK as of 30 September 2019

Simon Jordan signature

Simon Jordan
Senior Vice President International
Amicus Therapeutics UK Limited